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Apolipoprotein (apo)H (also known as p2 glycoprotein-I) is a 
glycoprotein synthesized by liver cells and it is present in the blood 
associated with plasma lipoproteins. APOH displays a genetically 
determined structural polymorphism: three alleles ( APOH* 1, APOH*2, 
APOH*3) at a single locus on chromosome 17 code for different isoforms, 
and population studies have shown that APOH*2 is the most frequent 
allele. This paper assesses the relation between APOH phenotypes and 
plasma apoH levels in a population composed of 278 healthy subjects 
(243 H2/2, 32 H3/2, 2 H3/3, 1 H2/1; allele frequencies APOH*l 0.002, 
APOH*2 0.934, APOH*3 0.064) and 245 diabetics (212 H2/2, 30 H3/2, 3 
H3/3; allele frequencies APOH*2 0.927 and APOH*3 0.073). 
Determination of apoH levels by competitive ELISA gave a mean value 
of 26.3k9.8 mg/dl for all subjects, 22.6k7.7 in normals vs 30.6k 10.3 in 
diabetics (p=O.OOOl), and 23.0t7.9, 19.3k5.4 and 18.5k3.5 mg/dl for 
H2/2, H3/2 and H3/3 in normals and 31.1 
15.7 k9.0 mg/dl in diabetics, respectively. ANCOVA of the adjusted data 
revealed a significant difference in apoH levels for the three phenotypes in 
both the normal subjects (p=O.Ol) and the diabetics (p=0.02),. 
ANCOVA of the whole samples of subjects, controlling for diabetes as 
well as age, sex and total cholesterol, indicated a substzntial effect of 
phenotype, independent of the other variables ( p  =0.0007). 
10.1, 28.2k 10.8 and 
ApoH, also known as p2 glycoprotein-I, is a single, 
approximately 50 kDa chain glycoprotein (Lozier 
et al. 1984) present in the blood in a mature 326 
amino acid form and associated with plasma lipo- 
proteins to the extent of 35% (Polz & Kostner 
1979). Its chemical and physical characteristics, 
particularly its affinity for negatively charged molec- 
ules, suggest that apoH is a coagulation inhibitor. 
It does, in fact, inhibit ADP-induced platelet 
aggregation (Nimpf et al. 1987), platelet prothrom- 
binase activity (Nimpf et al. 1986), and contact 
activation of the coagulation pathway (Schousboe 
1985). Its role in lipid metabolism has been exam- 
ined by several workers (Nakaya et al. 1980, Wurm 
et al. 1982, Eichner et al. 1989a, Kamboh & Ferrell 
1991). The in vivo and in vitro data indicate that it 
is involved in triglyceride (Tg) metabolism (Nakaya 
et al. 1980, Wurm et al, 1982). Many studies have 
shown that apoH is an obligate cofactor for binding 
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some groups of antibodies to anionic phospholipids 
(McNeil et al. 1990, Jones et al. 1992, Gharavi et al. 
1992, Hunt et al. 1993, Roubey 1994, Kamboh et al. 
1995). When present in patients with autoimmune 
diseases, these antibodies are associated with throm- 
bosis episodes (Love & Santoro 1990). It has 
recently been shown that apoH itself may be the 
antigenic determinant of autoantibodies thought to 
be responsible for occlusion (Viard et al. 1992), but 
the relation between apoH level and thrombosis 
(Bancsi et al. 1992) is uncertain, whereas a relation 
between apoH level and cholesterol (Chol) level has 
recently been observed in dyslipidaemia ( McNally 
et al. 1994). Plasma apoH levels are about 20 mg/dl 
(Propert 1978). 
APOH displays a genetically determined struc- 
tural polymorphism. Three alleles ( APOH* 1, 
APOH*2, APOH*3) in Caucasians (plus APOH*4 
in blacks only) a t  a single locus on chromosome 17 
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code for isoforms identified by isoelectric focusing 
electrophoresis (IEF) and immunoblotting 
(Kamboh et al. 1988). Population studies have 
shown that APOH*2 is the most frequent allele 
(Kamboh et al. 1988, Kamboh et al. 1991, Saha 
et al. 1992, Cassader et al. 1994), and that allele 
distribution shows ethnic variability (Crews et al. 
1991, Kamboh et al. 1991, Cleve et al. 1992, Crews 
et al. 1993). The relation between APOH phenotype 
and plasma Tg levels is still a matter of discussion 
(Sepehrnia et al. 1989, Eichner al. 1989b, Kaprio 
et al. 1991, Saha et al. 1993, Cassader et al. 1994). 
This paper assesses the relation between APOH 
alleles and plasma apoH levels in a Piedmont popu- 
lation consisting of 278 healthy and 245 diabetic 
subjects, in view of our personal observation of a 
link between apoH and this disease (Cassader 
et al. 1997). 
Materials and methods 
Materials 
All the materials were analytical grade. 
Nitrocellulose sheets were purchased from Bio-Rad 
(Bio-Rad Laboratories, Milan, Italy). Goat anti- 
rabbit IgG (alkaline phosphatase conjugated) was 
from Sigma-Chemical Co. (St. Louis, MI, USA), 
rabbit anti-Apo H antiserum was purchased from 
Istituto Behring (Scoppito, Italy), and the alkaline 
phosphatase conjugate substrate kit from Bio-Rad. 
Subjects 
A total of 278 unrelated subjects was enrolled from 
the University of Turin’s Department of Internal 
Medicine staff and its blood bank donors. The 
inclusion criteria were: absence of diabetes, liver 
and kidney diseases, altered thryoid function, and 
taking drugs affecting lipid metabolism. The only 
subject carrying the APOH* 1 allele was not consid- 
ered for statistical analysis. The 245 diabetics were 
outpatients at the department’s diabetological sec- 
tion. Diabetes was diagnosed in accordance with 
the WHO criteria. It is treated free in Italy and the 
patients can thus be regarded as representative of 
the Piedmont Region. They consisted of 129 non- 
insulin-dependent (NIDDM ) subjects receiving oral 
hypoglycaemising agents (98 patients) or diet man- 
agement alone (31 patients), and 116 insulin- 
dependent (IDDM) subjects usually treated with 
prompt insulin plus one slow insulin in the evening. 
Glycosylated haemoglobin ( HbA,,) was determined 
by high-pressure liquid chromatography ( HPLC ) 
(Bio-Rad, Diamat Model 723 Analyzer). Body mass 
index (BMI) was evaluated as body weight (kg) 
divided by height squared (m2). 
Plasma lipid determinations 
Blood samples ( 1  mg/ml EDTA-Na,) were centri- 
fuged for 30min at 2500 rev/min and 4°C in a 
Beckman J6B centrifuge (Beckman, Palo Alto, CA, 
USA) and stored at -20°C until processed. Chol 
and Tg were measured enzymatically (Poli 
Diagnostici, Milan, Italy), HDL-cholesterol was 
determined after precipitation of Apo B-containing 
lipoproteins with heparin and manganese chloride 
by means of automated enzymatic methods with a 
Shimadzu CL-7000 (Shimadzu Instruments, Kyoto, 
Japan). Plasma samples if not immediately used 
were stored at -70°C for at least 6 months. 
Determination of apoH phenotype 
This was done with a previously described modi- 
fication (Cassader et al. 1994) of Kamboh et al.’s 
method (Kamboh et al. 1988). Briefly, 10 pl plasma 
were delipidated in 5 ml acetone-ethanol 1 : 1 (v/v) 
at - 20°C for 2 h, resuspended in acetone-ethanol, 
washed with cold ether and dried under nitrogen. 
Pellets were incubated in 100 pl 0.01 M TRIS-HCl, 
3M urea and isoelectrofocused on polyacrylamide 
gel (T=5%, C=3.33%, urea 3M, pH=4-8) (Bio- 
Phoresis [ TM] horizontal electrophoresis cell, Bio- 
Rad), using a Model 3000/300 Power Supply. 
Focusing was carried out under 10 W constant 
power for 3 h. After the run, the proteins were 
transferred overnight onto 0.45-pm pore size nitro- 
cellulose membrane by simple diffusion. The nitro- 
cellulose was then incubated with rabbit anti-apoH 
antiserum (Istituto Behring) (1 : 2000, v/v, as first 
antibody) and goat anti-rabbit IgG conjugated to 
alkaline phosphatase (Sigma) ( 1 : 6000, v/v, second- 
ary antibody). The nitrocellulose was developed at 
room temperature according to the kit manufac- 
turer’s instructions (Bio-Rad). 
Determination of apoH levels 
Plasma apoH was determined with a competitive 
ELISA. Pure apoH was obtained from pooled 
human plasma by affinity chromatography and 
eiution electro-phoresis as described elsewhere 
(Gambino et al. 1996). Rabbit anti-apoH antibodies 
(Istituto Behring) were diluted 1 : 8000 with 0.05 M 
carbonatefiicarbonate buffer pH 9.5, and 100 p1 
were pipetted into each well of a 96-well microtitre 
plate. This was then sealed and left at 37°C for 1 h. 
Washing with 0.02 M sodium phosphate pH 7.8, 
0.15 M NaCl (PBS) to remove unbound antibodies 
was followed by blockade of the remaining sites by 
incubation with 350 pl 4% bovine serum albumin 
(BSA) in PBS for 1 h at 37°C. Unknown plasma 
samples and standards (obtained with serial dilution 
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from the stock solution of pure apoH) were diluted 
in assay buffer solution before assay. The optimum 
ELISA conditions were: 50 pl standards of apoH 
or plasma diluted 400-fold and 50 pl purified apoH 
labelled with horseradish peroxidase diluted 
1000-fold. Samples were pipetted into the wells of 
a precoated microtitre plate, which was then covered 
and incubated for 2.5 h at 37°C. The plate was 
washed six times and developed with 1 mg/ml 
p-nitrophenol phosphate in 0.05 M phosphate- 
citrated buffer pH 5.0. Well absorbance was meas- 
ured with a Bio-Rad 3550 reader at 490nm and 
serum concentrations were expressed in mg/dl. The 
working range was from 1.9 to 120 mg/dl. The 
intra-assay coefficient of variation (CV) of our 
competitive ELISA was calculated from the results 
of 10 pairs of wells in a single assay. The inter- 
assay CV was calculated from the results of pairs 
of wells in five assays. In the absence of appropriate 
control plasma for apoH, accuracy was determined 
from the recovery obtained after addition of our 
isolated apoH in known concentrations to normal 
plasma. 
Statistics 
Fisher’s test (Kendall & Stuart 1979) was used to 
compare the observed vs. expected phenotype fre- 
quencies, according to Hardy-Weinberg equilib- 
rium. The null hypothesis that APOH locus does 
not affect apoH plasma levels was tested by analysis 
of variance (ANOVA) performed on the three 
phenotypes (H2/2, H3/2, H3/3). In order to adjust 
for the effect of potentially confounding variables, 
which could be unevenly distributed among the 
three phenotypes, and therefore explain the 
observed differences in apoH levels, we performed 
analysis of covariance (ANCOVA), using age, 
gender, body mass index and total cholesterol as 
covariates. When simultaneous analysis was made 
on both groups of subjects, the means were adjusted 
also for presence of diabetes. 
To test the hypothesis that a trend in apoH levels 
exists when the number of copies of allele APOH*3 
in the phenotype increases from zero to two, we 
performed linear regression analysis on adjusted 
data. 
To test whether this effect is different in normal 
and diabetic subjects (i.e. if the regression coefficient 
differs in the two groups), we checked the sigifi- 
cance of the interaction term between number of 
APOH*3 allele and presence of diabetes. The aver- 
age effects of APOH*2 and APOH*3 on these levels 
were calculated in accordance with Boenvinkle 
et al.’s formula (Boenvinkle et al. 1988). 
Results 
APOH phenotypes were determined in 278 normal 
subjects (243 H2/2, 32 H3/2, 2 H3/3, 1 H2/1) and 
245 diabetics (212 H2/2, 30 H3/2, 3 H3/3). Allele 
frequencies were APOH*l 0.002, APOH*2 0.934 
and APOH*3 0.064 in normals; APOH*2 0.927 and 
APOH*3 0.073 in diabetic subjects. Fisher’s test 
did not reveal any significant differences in these 
frequencies from those expected assuming Hardy- 
Weinberg equilibrium. 
Determination of apoH levels by competitive 
ELISA gave a mean value of 26.3 f9.8 mg/dl for 
all subjects, 22.6k7.7 in normals vs 30.6f 10.3 in 
diabetics ( p =  0.0001 ). The clinical and metabolic 
data for the two groups are set out in Table 1. 
Table 2 reports apoH raw means divided by group 
and APOH phenotype. ANCOVA of data adjusted 
for age, sex, BMI and total cholesterol is reported 
in Table 3, and shows a significant effect of pheno- 
type on apoH levels in both groups of subjects. The 
agreement between raw and adjusted means shows 
that the interference of covariates is not very import- 
ant. No significant association was found between 
apoH levels and gender, age or Tg levels, in either 
normal or diabetic subjects. 
An apparently decreasing trend of apoH levels, 
Table 1. General particulars and plasma lipoprotein values (in mg/dl) in the normal 
and diabetic subjects (mean+ SO) 
Normals Diabetics 
n 277 245 
M/F 139/138 136/109 
Age 48 7 k 2 0  1 49 9 f 19 5 
260f47 243f31 BMI 
HbA,, ( % I  - 87 f1 8 
Tg 131 +lo1 118f79 
Chol 222 f 43 198f42 
HDL-Chol 576f128 50 6 f 15 5 
ApoH 226+77 30 6 f 10 3 
BMI = body mass index 
HbA, =glycosylating haemoglobin 
Tg = triglyceride 
Chol =cholesterol 
HDL= high density lipoprotein 
ApoH =apolipoprotein H 
Table 2. Apolipoprotein H (apoH) levels according to APOH phenotype in normal 
and diabetic subjects (SEM=standard error of the mean) 
~~ ~~ 
H212 H312 H313 
n Mean n Mean n Mean 
Group 1%) (SEMI (Yo) (SEM) 1%) (SEMI 
Normal 243 230 32 19 3 2 18 5 
(87 71 (0 5) ( 1 1  61 I1 0) I0 7) (2 5) 
Diabetics 245 31 1 30 28 2 3 15 7 
(86 5) (07 )  (122) (201 (1 2) (5 1) 
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Table 3. Analysis of covariance (ANCOVA) adjusting for age. sex. body mass index 
and total cholesterol. Apolipoprotein H levels are reported as adjusted means 
and (SEMI 
ANCOVA 
Group H2/2 H3/2 H3/3 F-value P-value 
Normal 23.0 19.1 18.1 4.50 0.01 
Diabetic 31.1 28.2 16.4 3.90 0.02 
10.51 11.4) (5.41 
10.7) (1.91 15.91 
when the number of APOH*3 alleles in the pheno- 
type increased, was observed in both normal and 
diabetic subjects (Table 3). The significance of this 
trend was checked by linear regression in the two 
groups separately, and in the whole sample after 
including also the presence of diabetes as a covari- 
ate. The results are shown in Table4 and are 
consistent with a cumulative effect of the dose of 
APOH*3 alleles. 
To test whether the regression coefficients in 
normal and diabetic subjects are significantly 
different, as suggested by the means shown in 
Table 2, we computed the interaction term between 
the number of APOH*3 alleles and the presence of 
diabetes. The resulting coefficient (0.66 f2.08) is 
not significantly different from zero (p = 0.79, thus 
indicating that our data do not support the hypo- 
thesis of a different effect of APOH*3 allele in the 
two groups. 
The average effect of APOH*3 allele was to 
reduce apoH levels by 3.59 (normals) and 3.38 
(diabetics) mg/dl, whereas that of APOH*2 was to 
increase them by 0.23 and 0.33 mg/dl respectively. 
It can also be estimated that 2.5% of the between- 
individual variability of apoH levels was attribut- 
able to differences in phenotype. 
Discussion 
Genetic and environmental factors control plasma 
lipoprotein levels (Lusis et al. 1988). As components 
of the lipoproteins, apolipoproteins can increase the 
risk of the appearance and development of athero- 
sclerosis (Sedlis et al. 1986). Our data show that 
Table 4. Regression analysis of apolipoprotein H plasma levels versus number of 
H'3 alleles. Data adjusted for age, gender, body mass index (BMl) and total 
cholesterol 
Regression Standard 
Group coefficient error P-value 
~~ 
Normals -3.51 1.25 0.005 
Diabetics -4.20 1.69 0.013 
All' -3.85 1.04 0.0002 
Values adjusted for age, sex. 8MI. total cholesterol and diabetes 
apoH levels are under the control of at least two 
alleles in a population composed of 278 normal and 
245 diabetic subjects. Their levels are higher in those 
homozygous for APOH*2 and lower in those homo- 
zygous for APOH*3. This effect is independent of 
age, sex, diabetes, BMI and total Chol. Diabetes, 
in fact, seems to increase plasma apoH levels signi- 
ficantly, and they are also correlated with those of 
total Chol (McNally et al. 1994). The decreasing 
trend of plasma apoH levels, according to the 
number of APOH*3 alleles in the phenotype, is 
statistically significant in both groups of subjects, 
although there are some dissimilarities: in normals 
the main difference among the three phenotypes is 
between H2/2 and H3/2 subjects, while in diabetics 
the main reduction is between H3/2 and H3/3 
subjects. However, there are by far too few 
APOH*3 homozygous individuals to allow pairwise 
comparison between phenotypes, and in this condi- 
tion it is not possible to reject the hypothesis of a 
codominant effect of allele APOH*3. 
ApoH seems to be involved in lipid metabolism 
and coagulation (Nakaya et al. 1980, Wurm et al. 
1982, Eichner et al. 1989a, Roubey 1994, Kamboh 
& Ferrell 1991), and also as a cofactor for the 
formation of antiphospholipid antibodies in some 
autoimmune diseases (Roubey 1994). A correlation 
has equally been sought between its plasma levels 
and various disorders, especially those related to 
lipid metabolism and coagulation (Roubey 1994). 
Increased levels have been reported in dyslipidaemia 
(McNally et al. 1994), while no association between 
apoH levels and other metabolic disease has so far 
been observed (Bancsi et al. 1992). 
Recent studies have evaluated the relation 
between APOH polymorphism and plasma lipid 
levels (Sepehrnia et al. 1989, Eichner et al. 1989b, 
Kaprio et al. 1991, Saha et al. 1993, Cassader et al. 
1994). No association has so far been established, 
however, between phenotype and apoH levels. 
No reason can readily be found for the observa- 
tion that apoH levels are markedly increased in 
diabetics, even when the data are corrected for 
confounding variables. In this connection, it will be 
recalled that variations in plasma Lp(a) in diabetes 
have been reported by some workers (Ramirez et al. 
1992), though not by others (Schernthaner et al. 
1983), with differing results in IDDM and NIDDM 
types, and a tendency towards higher values in 
poorly controlled IDDM patients (Haffner 1993). 
The conclusion reached in a recent review on the 
non-enzymatic glycation of Lp(a) was that this 
process increases the negative charge of the molecule 
(Makino et al. 1995), and hence its chemical and 
physical properties, but not its atherogenic poten- 
tial. It is clear that studies of similar glycation of 
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apoH in vitro would be of great assistance in 
explaining our results in diabetes. 
ApoH is synthesised in the liver and probably 
catabolised in the kidney. It is a highly glycosylated 
protein (Lee et al. 1983): glycosylation may thus 
increase in relation to blood glucose levels in dia- 
betic patients, prolonging apoH catabolism and 
hence influencing its circulating levels. We have 
demonstrated a relation between degree of glycosyl- 
ation and apoH levels, as indicated by the correla- 
tion between these levels and HbA1, in diabetics 
(Cassader et al. 1997). 
These findings require corroboration in other 
populations, since the allele frequency observed was 
similar to that reported by some workers, though 
not all (Saha et al. 1993). It would thus be of 
interest to determine whether there is a direct allele 
effect on apoH levels. Further studies are also 
needed to assess the ratio between apolipoprotein 
levels and the various alleles in disorders such as 
autoimmune diseases, in which apoH itself appears 
to be involved. 
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